The new digital pathology algorithm helps clinicians personalize treatment for patients with metastatic hormone-sensitive prostate cancer.
Tempus AI announced the clinical launch of the ArteraAI Prostate Test, a prognostic tool designed for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The test is Clinical Laboratory Improvement Amendments certified and College of American Pathologists accredited.
The test is the first digital pathology algorithm from an external developer to be available through the Tempus platform, according to a release from Tempus AI. It uses an artificial intelligence algorithm to evaluate a patient’s clinical data and histopathology biopsy images. This process generates a personalized risk estimate for prostate cancer-specific mortality.
According to the company, the test aims to address a gap in care for the approximately 25,000 patients diagnosed with metastatic prostate cancer in the US each year. By pairing Artera’s pathology-based results with genomic results from next-generation sequencing assays, clinicians receive what the company describes as a “far more comprehensive assessment” of the disease.
“From the start of our Tempus collaboration, our goal has been to deliver Artera’s AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way,” says Amanda Lowe, chief commercial officer at Artera, in a release.
The ArteraAI Prostate Test is available as an add-on to the Tempus solid tumor portfolio.
“By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy, helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey,” says Laura Elster, chief commercial officer of diagnostics at Tempus, in a release.
ID 186175420 © Noipornpan | Dreamstime.com
